RE:RE:RE:RE:News better be very good on tuesday
I have to think that the best case scenario on Tuesday is that we get evidence that 4050 is moving meaningful Biomarkers, similar to observed changes in the early / middle stages of the animal model. I doubt they have biopsied anyones Pancreas ! so it could very well be something as simple as measured Glucose levels being reduced.....where there is enough evidence to suggest that the drug is having the intended effect, and then it remains to be seen if it actually meaningfully changes the Organ itself.
From an analyst / market perspective, none of these guys have given 4050 ANY meaingful chance of success. Most have handicapped it at 10%, given average trial failure rates.
But as Pierre said, IF we move the Biomarkers, and it appears we are on the path to the same endgame, THEN we HAVE A DRUG.
Despite alot of criticism and teeth gnashing from myselft and others to get a deal done and stop the seemingly endless stream of diluation, Pierre very well have his day on Tuesday, where he can show the world HE and his staff we right. They have a drug, they are getting the desired effect in humans... and now they GET THEIR PRICE. To Sah's point, If all goes as planned, and they can in fact prove with human data that they have substantially DE RISKED the whole 4050 development process, THEN they start doing deals. Its been suggested that they have been working on a deal in Asia for some time, whereby they would license the drug to a specific geography. Its the derisking of the drug that will get this and other deals done. Which is why this date and the dominos that fall after will light the afterburners.
TTMA